RGN-259

DRUG5 trials

Sponsors

ReGenTree, LLC

Conditions

Dry EyeDry Eye SyndromeDry Eye SyndromesNeurotrophic Keratopathy

Phase 2

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1

CompletedNCT02597803

ReGenTree, LLCDry Eye Syndrome

Start: 2015-09-30End: 2016-07-31Updated: 2019-10-17

Phase 3

Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1

TerminatedNCT02600429

ReGenTree, LLCNeurotrophic Keratopathy

Start: 2015-09-17End: 2020-03-09Updated: 2023-08-30

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2

CompletedNCT02974907

ReGenTree, LLCDry Eye Syndrome

Start: 2016-11-30End: 2018-03-31Updated: 2022-01-05

Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-3

CompletedNCT03937882

ReGenTree, LLCDry Eye, Dry Eye Syndromes

Start: 2019-05-24End: 2021-10-07Updated: 2026-08-28

Assessment of the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of NK: SEER-2

RecruitingNCT05555589

ReGenTree, LLCNeurotrophic Keratopathy

Start: 2023-04-11End: 2026-05-30Target: 70Updated: 2025-12-23